| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 72789-0473-18 | 72789-0473 | PredniSONE | PredniSONE Tablets, USP, 20 mg | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 6, 2026 | In Use | |
| 70518-4038-08 | 70518-4038 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 3, 2026 | In Use | |
| 83831-0143-01 | 83831-0143 | Fluorouracil | FAVLYXA | 25.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Apr 1, 2026 | In Use | |
| 85766-0194-10 | 85766-0194 | Triamcinolone Acetonide | Triamcinolone Acetonide | 400.0 mg/10mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intramuscular | Apr 1, 2026 | In Use | |
| 70748-0273-01 | 70748-0273 | Pegfilgrastim-unne | ARMLUPEG | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Apr 1, 2026 | In Use | |
| 83831-0144-05 | 83831-0144 | Etoposide | Avopef | 100.0 mg/5mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Apr 1, 2026 | In Use | |
| 55513-0099-01 | 55513-0099 | Pegfilgrastim | Neulasta | 4.0 mg/.4mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Mar 31, 2026 | In Use | |
| 82293-0030-21 | 82293-0030 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 30, 2026 | In Use | |
| 85006-1755-01 | 85006-1755 | Bevacizumab-maly | ALYMSYS | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Mar 30, 2026 | In Use | |
| 82293-0030-31 | 82293-0030 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 30, 2026 | In Use | |
| 55154-2581-00 | 55154-2581 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 30, 2026 | In Use | |
| 14789-0126-05 | 14789-0126 | Cyclophosphamide | Cyclophosphamide | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 30, 2026 | In Use | |
| 14789-0125-05 | 14789-0125 | Cyclophosphamide | Cyclophosphamide | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 30, 2026 | In Use | |
| 82293-0030-10 | 82293-0030 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 30, 2026 | In Use | |
| 85006-1754-01 | 85006-1754 | Bevacizumab-maly | ALYMSYS | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Mar 30, 2026 | In Use | |
| 81033-0021-54 | 81033-0021 | prednisoLONE sodium phosphate | prednisoLONE sodium phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 27, 2026 | In Use | |
| 00904-7584-10 | 00904-7584 | Leucovorin Calcium | Leucovorin Calcium | 25.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Mar 27, 2026 | In Use | |
| 76346-0525-03 | 76346-0525 | Relacorilant | Lifyorli | 25.0 mg/1, 100.0 mg/1 | Chemotherapy | Glucocorticoid Receptor (GR) Antagonist | Oral | Mar 25, 2026 | In Use | ||
| 76346-0525-09 | 76346-0525 | Relacorilant | Lifyorli | 25.0 mg/1, 100.0 mg/1 | Chemotherapy | Glucocorticoid Receptor (GR) Antagonist | Oral | Mar 25, 2026 | In Use | ||
| 76346-0550-03 | 76346-0550 | Relacorilant | Lifyorli | 25.0 mg/1, 100.0 mg/1 | Chemotherapy | Glucocorticoid Receptor (GR) Antagonist | Oral | Mar 25, 2026 | In Use | ||
| 76346-0450-01 | 76346-0450 | Relacorilant | Lifyorli | 25.0 mg/1, 100.0 mg/1 | Chemotherapy | Glucocorticoid Receptor (GR) Antagonist | Oral | Mar 25, 2026 | In Use | ||
| 76346-0550-09 | 76346-0550 | Relacorilant | Lifyorli | 25.0 mg/1, 100.0 mg/1 | Chemotherapy | Glucocorticoid Receptor (GR) Antagonist | Oral | Mar 25, 2026 | In Use | ||
| 76346-0425-01 | 76346-0425 | Relacorilant | Lifyorli | 25.0 mg/1, 100.0 mg/1 | Chemotherapy | Glucocorticoid Receptor (GR) Antagonist | Oral | Mar 25, 2026 | In Use | ||
| 50090-7933-06 | 50090-7933 | PREDNISONE | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 24, 2026 | In Use | |
| 69448-0026-63 | 69448-0026 | Pegfilgrastim-cbqv | UDENYCA | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Mar 23, 2026 | In Use |
Found 12393 results — Export these results
Home